Micheroli, Raphael http://orcid.org/0000-0002-8918-7304
Kissling, Seraphina http://orcid.org/0000-0003-0619-0012
Bürki, Kristina
Möller, Burkhard http://orcid.org/0000-0001-8769-6167
Finckh, Axel http://orcid.org/0000-0002-1210-4347
Nissen, Michael J. http://orcid.org/0000-0002-6326-1764
Exer, Pascale
Bräm, René
Kyburz, Diego http://orcid.org/0000-0002-9560-109X
Rubbert-Roth, Andrea
Andor, Michael
Baraliakos, Xenofon http://orcid.org/0000-0002-9475-9362
de Hooge, Manouk http://orcid.org/0000-0002-0652-9808
Distler, Oliver http://orcid.org/0000-0002-0546-8310
Scherer, Almut http://orcid.org/0000-0001-7382-4092
Ciurea, Adrian http://orcid.org/0000-0002-7870-7132
Funding for this research was provided by:
University of Zurich
Article History
Received: 22 January 2023
Revised: 1 June 2023
Accepted: 1 June 2023
First Online: 8 June 2023
Declarations
:
: The study has been approved by the Ethics Commission of the Canton of Zurich (KEK-ZH-Nr. 2014–0439) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all patients.
: AC received honoraria for lectures from AbbVie and Novartis. AF received research grants to his institution from Abbvie, BMS, Galapagos, Eli Lilly and Pfizer, as well as consulting fees from Abbvie, AstraZeneca, BMS, Galapagos, Eli Lilly, Novartis, Merck Sharp & Dohme, Pfizer, Sandoz and Roche. ARR received honoraria for lectures and consultation from Abbvie, Amgen, BMS, UCB, Pfizer, Gilead, Eli Lilly, Novartis and Janssen. AS received consulting fees from Pfizer and support for attending meetings from Gilead. BM received speaking fees from Janssen, Eli Lilly, Novartis and Pfizer, support for attending meetings from Janssen and Pfizer and a research grant from Celgene. DK received consulting fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche and support for attending meetings from Janssen and Eli Lilly. MdH received grants from FWRO/FRSR and honoraria from UCB for participation in advisory board. MJN received consulting and/or speaking fees from Abbvie, Eli Lilly, Janssen, Novartis and Pfizer, as well as a research grant from Novartis. OD received consulting fees from Abbvie. PE received financial support from UCB for attending a meeting. RM received honoraria for lectures or presentations from Abbvie, Eli Lilly, Janssen, Gilead and Pfizer. KB, MA, RB, SK and XB declare they have no conflicts of interest.